Antiviral treatment in patients with advanced hepatitis C virus cirrhosis with sofosbuvir and either ledipasvir or daclatasvir, with or without ribavirin: observational cohort study

The Lancet ◽  
2016 ◽  
Vol 387 ◽  
pp. S26 ◽  
Author(s):  
Michelle Cheung ◽  
Graham Foster ◽  
William Irving ◽  
John McLauchlan ◽  
Alex Walker ◽  
...  
2019 ◽  
Vol 24 (30) ◽  
Author(s):  
Georgina Ireland ◽  
Sema Mandal ◽  
Matthew Hickman ◽  
Mary Ramsay ◽  
Ross Harris ◽  
...  

Background Monitoring trends in mortality for individuals diagnosed with hepatitis C virus (HCV) infection are important as we expand treatment and move towards World Health Organization elimination targets. Aim To estimate mortality rates for individuals aged ≥ 15 years diagnosed with HCV infection in England 2008–16. Methods An observational cohort study whereby death certificate information was linked to the Sentinel Surveillance of Blood Borne Virus Testing in England. Age-sex standardised mortality rates (ASMR) for individuals diagnosed with HCV infection (2008–16) were calculated and compared to the general population. Results Of 43,895 individuals with HCV infection, 2,656 (6.3%) died. All-cause ASMRs were 2,834.2 per 100,000 person years (PY), 2.3 times higher than in the general population. In individuals aged 30–69 years, all-cause mortality rates were 1,768.9 per 100,000 PY among individuals with HCV, 4.7 times higher than in the general population. ASMRs had not decreased between 2010 (2,992) and 2016 (2,340; p=0.10), with no change from 2014 (p = 0.058). ASMRs were 441.0 times higher for hepatitis, 34.4 times higher for liver cancer, 8.1 times higher for end stage liver disease and 6.4 times higher for external causes than in the general population. Conclusions Mortality was higher in individuals with diagnosed HCV infection compared to the general population, highlighting health inequalities. There is a need to improve HCV diagnosis, engagement in care and treatment rates. The high mortality from external causes highlights the importance of integrated health and social care strategies and addressing the needs of this vulnerable population.


2009 ◽  
Vol 16 (9) ◽  
pp. 659-665 ◽  
Author(s):  
N. Hansen ◽  
N. Obel ◽  
P. B. Christensen ◽  
H. Krarup ◽  
A. L. Laursen ◽  
...  

2017 ◽  
Vol 30 (12) ◽  
pp. 1253-1265 ◽  
Author(s):  
Paola Carrai ◽  
Cristina Morelli ◽  
Gabriella Cordone ◽  
Antonietta Romano ◽  
Mariarosa Tamé ◽  
...  

2022 ◽  
Vol 13 ◽  
pp. 204062232110676
Author(s):  
Ming-Han Hsieh ◽  
Tzu-Yu Kao ◽  
Ting-Hui Hsieh ◽  
Chun-Chi Kao ◽  
Cheng-Yuan Peng ◽  
...  

Background: For chronic hepatitis C (CHC) patients completing pegylated interferon (PegIFN)-α/ribavirin therapy, long-term liver histological changes remain largely unexplored. Methods: This observational cohort study included 85 CHC patients completing PegIFN-α/ribavirin therapy with liver biopsies performed at baseline and the end of surveillance (EOS). Median years between paired biopsies were 6.75 (interquartile range: 5.63–7.54). Results: In patients with baseline METAVIR fibrosis stages (F) <4 (able to undergo fibrosis progression; n = 77), cases achieving sustained virological response (SVR) ( n = 52) had a significantly lower rate of fibrosis progression than non-SVR cases ( n = 25) (3.8% versus 24.0%, p = 0.012). Among the entire cohort ( n = 85), the rate of activity response [METAVIR activity grades (A) decreasing or maintaining at A0] in SVR cases ( n = 59) was significantly higher than that in non-SVR cases ( n = 26) (94.9% versus 65.4%, p = 0.001). For SVR cases among the entire cohort, independent predictors of fibrosis clearance included baseline F <2 [odds ratio (OR) = 7.877, p = 0.042] and aspartate transaminase (AST) levels declining by >70% at EOS compared with baseline (OR = 9.013, p = 0.038). For non-SVR cases among the entire cohort, baseline AST levels >80 U/l and glucose levels ⩽ 105 mg/dl independently predicted significant fibrosis (F2/F3/F4) at EOS (OR = 12.558, p = 0.049) and activity response (OR = 17.741, p = 0.047), respectively. Conclusions: Among CHC patients completing PegIFN-α/ribavirin therapy, SVR lowers the risk of liver histological progression but does not guarantee fibrosis clearance. For SVR cases, those with baseline F ⩾ 2 or without significantly declined follow-up AST levels should be specifically monitored. As for non-SVR cases, those with a higher baseline AST or glucose level should preferentially receive retreatment.


Sign in / Sign up

Export Citation Format

Share Document